ATE373671T1 - Aminooxy-modifizierte oligonukleotide - Google Patents
Aminooxy-modifizierte oligonukleotideInfo
- Publication number
- ATE373671T1 ATE373671T1 AT98908488T AT98908488T ATE373671T1 AT E373671 T1 ATE373671 T1 AT E373671T1 AT 98908488 T AT98908488 T AT 98908488T AT 98908488 T AT98908488 T AT 98908488T AT E373671 T1 ATE373671 T1 AT E373671T1
- Authority
- AT
- Austria
- Prior art keywords
- aminooxy
- modified oligonucleotides
- moieties
- oligonucleotide
- oligonucleotides
- Prior art date
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3714397P | 1997-02-14 | 1997-02-14 | |
| US09/016,520 US6127533A (en) | 1997-02-14 | 1998-01-30 | 2'-O-aminooxy-modified oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE373671T1 true ATE373671T1 (de) | 2007-10-15 |
Family
ID=26688714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98908488T ATE373671T1 (de) | 1997-02-14 | 1998-02-13 | Aminooxy-modifizierte oligonukleotide |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6127533A (de) |
| EP (1) | EP0977767B1 (de) |
| JP (1) | JP4440346B2 (de) |
| KR (1) | KR100399743B1 (de) |
| AT (1) | ATE373671T1 (de) |
| AU (1) | AU740799B2 (de) |
| CA (1) | CA2278715C (de) |
| DE (1) | DE69838449T2 (de) |
| WO (1) | WO1998035978A1 (de) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| EP0728139B1 (de) | 1993-09-03 | 2003-08-13 | Isis Pharmaceuticals, Inc. | Aminoderivatisierte nukleoside und oligonukleoside |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| US6172209B1 (en) * | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6639062B2 (en) * | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| US6576752B1 (en) * | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| CA2329130A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
| US6326478B1 (en) | 1998-07-08 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
| US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DK1149109T3 (da) * | 1999-02-05 | 2010-01-11 | Ge Healthcare Bio Sciences | Fremgangsmåde til afbeskyttelse af oligonukleotider |
| RU2233844C2 (ru) | 1999-02-12 | 2004-08-10 | Санкио Компани Лимитед | Новые нуклеозидные и олигонуклеотидные аналоги |
| US6207819B1 (en) * | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| US6140124A (en) * | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
| US20040171566A1 (en) | 1999-04-06 | 2004-09-02 | Monia Brett P. | Antisense modulation of p38 mitogen activated protein kinase expression |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| US6277982B1 (en) | 1999-08-20 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates |
| US20050118618A1 (en) * | 1999-08-30 | 2005-06-02 | Dale Roderic M. | Method for detecting nucleic acid sequences |
| DE10100586C1 (de) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US6686461B1 (en) | 2000-03-22 | 2004-02-03 | Solulink Bioscience, Inc. | Triphosphate oligonucleotide modification reagents and uses thereof |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) * | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US6825338B2 (en) | 2001-03-30 | 2004-11-30 | Isis Pharmaceuticals, Inc. | Labeled oligonucleotides, methods for making same, and compounds useful therefor |
| WO2002102820A1 (en) | 2001-06-20 | 2002-12-27 | Nuevolution A/S | Nucleoside derivatives for library preparation |
| EP2186897B1 (de) | 2002-03-15 | 2016-02-17 | Nuevolution A/S | Eine verbesserte Methode zur Synthese von matritzenabhängigen Molekülen |
| US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
| AU2003247266A1 (en) | 2002-08-01 | 2004-02-23 | Nuevolution A/S | Multi-step synthesis of templated molecules |
| US20040038331A1 (en) * | 2002-08-23 | 2004-02-26 | Reddy M. Parameswara | Solid phase synthesis of biomolecule conjugates |
| WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
| US9534224B2 (en) | 2002-11-15 | 2017-01-03 | Trustees Of Boston University | Cis/trans riboregulators |
| US20040115634A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Modulation of stat 6 expression |
| CA2524495A1 (en) | 2003-06-03 | 2005-01-13 | Eli Lilly And Company | Modulation of survivin expression |
| EP3604537B1 (de) | 2003-06-13 | 2021-12-08 | Alnylam Europe AG | Doppelsträngige ribonukleinsäure mit erhöhter wirksamkeit in einem organismus |
| US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| BRPI0413930A (pt) | 2003-09-18 | 2006-10-24 | Isis Pharmaceuticals Inc | composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste |
| DK1670939T3 (da) | 2003-09-18 | 2010-03-01 | Nuevolution As | Fremgangsmåde til opnåelse af strukturel information om et kodet molekyle og fremgangsmåde til udvælgelse af forbindelser |
| WO2005056761A2 (en) * | 2003-12-05 | 2005-06-23 | Massachusetts Institute Of Technology | REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi |
| WO2005085443A2 (en) * | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| EP1735009A4 (de) | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | Irna mittel targeting vegf |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| EP2540734B1 (de) | 2004-04-05 | 2016-03-30 | Alnylam Pharmaceuticals, Inc. | Prozess und Reagenzien für Oligonukleotidsynthese und -reinigung |
| AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| WO2006086821A1 (en) | 2004-10-20 | 2006-08-24 | Antisense Therapeutics Ltd | ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION |
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| US7244829B2 (en) * | 2004-11-08 | 2007-07-17 | Gem Pharmaceuticals, Llc | Compositions and processes for preparing 13-deoxy-anthracyclines |
| US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
| US7923206B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
| US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
| US7585968B2 (en) | 2005-03-28 | 2009-09-08 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to thymus and activation-regulated chemokine (TARC) |
| WO2006113743A2 (en) * | 2005-04-18 | 2006-10-26 | Massachusetts Institute Of Technology | Compositions and methods for rna interference with sialidase expression and uses thereof |
| EP1941059A4 (de) | 2005-10-28 | 2010-11-03 | Alnylam Pharmaceuticals Inc | Zusammensetzungen und verfahren zur hemmung der expression des huntingtin-gens |
| AU2006311725B2 (en) * | 2005-11-04 | 2011-11-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of NAV1.8 gene |
| CA2626690A1 (en) | 2005-11-09 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
| DK3018206T3 (da) | 2005-12-01 | 2021-11-15 | Nuevolution As | Enzymatic encoding methods for efficient synthesis of large libraries |
| US20090317802A1 (en) * | 2005-12-09 | 2009-12-24 | Bhatia Sangeeta N | Compositions and Methods to Monitor RNA Delivery to Cells |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
| EP2492684B1 (de) | 2006-06-02 | 2016-12-28 | President and Fellows of Harvard College | Neugestaltung von Proteinoberflächen |
| US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
| CA2663601C (en) | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
| US20110294782A1 (en) | 2006-11-10 | 2011-12-01 | Massachusetts Institute Of Technology | Small molecule pak inhibitors |
| US20080213377A1 (en) * | 2006-12-08 | 2008-09-04 | Bhatia Sangeeta N | Delivery of Nanoparticles and/or Agents to Cells |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| WO2008151024A1 (en) * | 2007-05-30 | 2008-12-11 | Brigham Young University | Protein kinase-binding nucleosides and associated methods |
| EP2620157A3 (de) | 2007-10-12 | 2013-10-16 | Massachusetts Institute of Technology | Impfstoffnanotechnologie |
| US7732659B2 (en) * | 2007-11-20 | 2010-06-08 | Genetic Services, Inc. | Injecting Drosophila embryos |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| AU2009243187C1 (en) * | 2008-04-28 | 2015-12-24 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| US20110119781A1 (en) * | 2008-07-15 | 2011-05-19 | Birgit Bramlage | Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes |
| US20100076183A1 (en) * | 2008-09-22 | 2010-03-25 | Dellinger Douglas J | Protected monomer and method of final deprotection for rna synthesis |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| CN102216457A (zh) * | 2008-11-17 | 2011-10-12 | 霍夫曼-拉罗奇有限公司 | 抑制凝血因子vii基因的表达的组合物和方法 |
| CA2745811C (en) | 2008-12-04 | 2021-07-13 | Joseph Collard | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| EP2393926A1 (de) | 2009-02-03 | 2011-12-14 | F. Hoffmann-La Roche AG | Zusammensetzungen und verfahren zur hemmung der ptp1b-genexpression |
| JP5463055B2 (ja) * | 2009-02-27 | 2014-04-09 | 公益財団法人相模中央化学研究所 | フタルイミド誘導体及びそれらの製造方法 |
| JP5418360B2 (ja) * | 2009-03-27 | 2014-02-19 | 日油株式会社 | ポリオキシアルキレン誘導体の製造方法 |
| EP2424877A4 (de) | 2009-04-28 | 2013-01-02 | Harvard College | Suprageladene proteine zur zellpenetration |
| KR20120069610A (ko) * | 2009-05-15 | 2012-06-28 | 에프. 호프만-라 로슈 아게 | 글루코코르티코이드 수용체(ｇｃｒ) 유전자의 발현을 억제하는 조성물 및 방법 |
| WO2010148065A2 (en) * | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
| WO2011054939A2 (en) | 2009-11-09 | 2011-05-12 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of kif10 genes |
| US20110152349A1 (en) | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
| TW201129365A (en) | 2010-02-05 | 2011-09-01 | Hoffmann La Roche | Compositions and methods for inhibiting expression of IKK2 genes |
| EP2558577B1 (de) | 2010-04-16 | 2018-12-12 | Nuevolution A/S | Bifunktionelle komplexe und verfahren zur herstellung sowie verwendung derartiger komplexe |
| MX352324B (es) | 2010-05-26 | 2017-11-17 | Selecta Biosciences Inc Star | Vacunas multivalentes de nanovehiculos sinteticos. |
| EP2851426B1 (de) | 2010-10-18 | 2018-08-22 | Arrowhead Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Hemmung der Expression von RRM2-Genen |
| CN106924216A (zh) | 2011-01-24 | 2017-07-07 | 安特里奥公司 | 纳米颗粒组合物、其制剂和它们的用途 |
| TR201905477T4 (tr) | 2011-01-24 | 2019-05-21 | Anterios Inc | Nano-parçacık bileşimler. |
| US9284343B2 (en) | 2011-04-04 | 2016-03-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
| EP2726613B1 (de) | 2011-06-30 | 2018-08-08 | Arrowhead Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der genexpression des hepatitis-b-virus |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CA3188691A1 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | 3'end caps for rnai agents for use in rna interference |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| WO2015050871A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compounds to treat hepatitis b virus |
| EP4056594A1 (de) | 2014-01-10 | 2022-09-14 | Birdie Biopharmaceuticals Inc. | Verbindungen und zusammensetzungen für die immuntherapie |
| EP4039807A1 (de) | 2014-06-10 | 2022-08-10 | Erasmus University Rotterdam Medical Center | Zur behandlung der pompe-krankheit nützliche antisense-oligonukleotide |
| EP3166976B1 (de) | 2014-07-09 | 2022-02-23 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1-kombinationen zur tumorbehandlung |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| AU2016271101B2 (en) | 2015-05-31 | 2021-04-01 | Curegenix Corporation | Combination compositions for immunotherapy |
| CA2991894A1 (en) | 2015-07-10 | 2017-01-19 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
| EP3332007A4 (de) | 2015-08-07 | 2019-07-17 | Arrowhead Pharmaceuticals, Inc. | Rnai-therapie gegen infektion mit dem hepatitis-b-virus |
| EP3387127A1 (de) | 2015-12-07 | 2018-10-17 | Erasmus University Medical Center Rotterdam | Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
| NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
| US10369167B2 (en) | 2016-11-01 | 2019-08-06 | City Of Hope | Continuously expressed therapeutic RNAs for targeted protein binding and methods for their use |
| EP3768702A4 (de) | 2018-03-22 | 2022-05-04 | Board of Regents, The University of Texas System | Therapie mit löslichem interleukin-7-rezeptor (sil7r) zur behandlung von autoimmunerkrankungen und krebs |
| EP4081638A1 (de) | 2019-12-23 | 2022-11-02 | ProQR Therapeutics II B.V. | Antisense-oligonukleotide zur nukleotid-deaminierung bei der behandlung von morbus stargardt |
| EP4479535A1 (de) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide-oligonukleotide zur nukleinsäureeditierung bei der behandlung von hypercholesterinämie |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5430136A (en) * | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| EP0216860B1 (de) * | 1985-03-15 | 1992-10-28 | SUMMERTON, James | Stereoregulare polynukleotiden bindende polymere |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0260032B1 (de) * | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere |
| US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| WO1989009221A1 (en) * | 1988-03-25 | 1989-10-05 | University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
| EP0339842B1 (de) * | 1988-04-27 | 1996-11-06 | Isis Pharmaceuticals, Inc. | Oligoribonukleotid-Derivate und ihre Anwendung als antivirale Mittel |
| US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) * | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| DE3916871A1 (de) * | 1989-05-24 | 1990-11-29 | Boehringer Mannheim Gmbh | Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren |
| KR920701230A (ko) * | 1989-06-05 | 1992-08-11 | 원본미기재 | 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법 |
| JPH05504552A (ja) * | 1989-10-24 | 1993-07-15 | ギリアド サイエンシズ，インコーポレイテッド | ２’位が改変されたオリゴヌクレオチド |
| US5264562A (en) * | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5177198A (en) * | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5514786A (en) * | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
| ATE271064T1 (de) * | 1990-01-11 | 2004-07-15 | Isis Pharmaceuticals Inc | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
| US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5587361A (en) * | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5457191A (en) * | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5591623A (en) * | 1990-08-14 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5359051A (en) * | 1990-01-11 | 1994-10-25 | Isis Pharmaceuticals | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA |
| US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| US5506351A (en) * | 1992-07-23 | 1996-04-09 | Isis Pharmaceuticals | Process for the preparation of 2'-O-alkyl guanosine and related compounds |
| US5459255A (en) * | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| US5321131A (en) * | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| DE4037363A1 (de) * | 1990-04-09 | 1991-10-10 | Europ Lab Molekularbiolog | 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten |
| US5470967A (en) * | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| AU7998491A (en) * | 1990-05-25 | 1991-12-31 | Gilead Sciences, Inc. | Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna |
| US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5223618A (en) * | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| ATE154246T1 (de) * | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
| US5138045A (en) * | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5386023A (en) * | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5218105A (en) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| ES2259177T3 (es) * | 1990-08-13 | 2006-09-16 | Isis Pharmaceuticals, Inc. | Oligonucleotidos modificados en el azucar que detectan y modulan la expresion genica. |
| JPH06501843A (ja) * | 1990-08-14 | 1994-03-03 | アイシス・ファーマシューティカルス・インコーポレーテッド | アンチセンスオリゴヌクレオチドによるインフルエンザａ型ウイルス，アン・アーバｈ２ｎ２株の阻害 |
| BR9106751A (pt) * | 1990-08-16 | 1993-08-17 | Isis Pharmaceuticals Ind | Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus |
| US5442049A (en) * | 1992-11-19 | 1995-08-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
| US5214134A (en) * | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| CA2092002A1 (en) * | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
| US5242906A (en) * | 1991-04-22 | 1993-09-07 | University Of North Carolina At Chapel Hill | Antisense oligonucleotides against Epstein-Barr virus |
| WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
| WO1992022651A1 (en) * | 1991-06-14 | 1992-12-23 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| US5582986A (en) * | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| US5576302A (en) * | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| JP2823959B2 (ja) * | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
| US5359044A (en) * | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5464746A (en) * | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| US5543507A (en) * | 1992-03-05 | 1996-08-06 | Isis Pharmaceuticals, Inc. | Covalently cross-linked oligonucleotides |
| US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| EP0651759B1 (de) * | 1992-07-23 | 2003-12-10 | Isis Pharmaceuticals, Inc. | 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
| IL107150A0 (en) * | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| GB9304618D0 (en) * | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| US5571902A (en) * | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5510476A (en) * | 1994-07-07 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Carbocation scavenging during oligonucleotide synthesis |
| US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
| US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
-
1998
- 1998-01-30 US US09/016,520 patent/US6127533A/en not_active Expired - Lifetime
- 1998-02-13 AU AU66513/98A patent/AU740799B2/en not_active Expired
- 1998-02-13 KR KR10-1999-7007378A patent/KR100399743B1/ko not_active IP Right Cessation
- 1998-02-13 WO PCT/US1998/002405 patent/WO1998035978A1/en active IP Right Grant
- 1998-02-13 DE DE69838449T patent/DE69838449T2/de not_active Expired - Lifetime
- 1998-02-13 CA CA002278715A patent/CA2278715C/en not_active Expired - Lifetime
- 1998-02-13 EP EP98908488A patent/EP0977767B1/de not_active Expired - Lifetime
- 1998-02-13 JP JP53583898A patent/JP4440346B2/ja not_active Expired - Lifetime
- 1998-02-13 AT AT98908488T patent/ATE373671T1/de not_active IP Right Cessation
-
2000
- 2000-01-05 US US09/477,902 patent/US6194598B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998035978A1 (en) | 1998-08-20 |
| AU740799B2 (en) | 2001-11-15 |
| CA2278715A1 (en) | 1998-08-20 |
| EP0977767A4 (de) | 2003-04-23 |
| KR100399743B1 (ko) | 2003-09-29 |
| JP2001512457A (ja) | 2001-08-21 |
| DE69838449D1 (de) | 2007-10-31 |
| DE69838449T2 (de) | 2008-06-12 |
| US6194598B1 (en) | 2001-02-27 |
| US6127533A (en) | 2000-10-03 |
| EP0977767A1 (de) | 2000-02-09 |
| JP4440346B2 (ja) | 2010-03-24 |
| EP0977767B1 (de) | 2007-09-19 |
| KR20000071091A (ko) | 2000-11-25 |
| CA2278715C (en) | 2008-12-02 |
| AU6651398A (en) | 1998-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69838449D1 (de) | Aminooxy-modifizierte oligonukleotide | |
| DK0691980T3 (da) | 7-deazapurinmodifiderende oligonukleotider | |
| ES2192672T3 (es) | Nuevos analogos de nucleotidos. | |
| BR9707529A (pt) | Oligunucleotìdeo especificamente hibridizável com dna ou rna. | |
| DK1178999T3 (da) | L-RIBO-LNA-analoger | |
| DE69806003D1 (de) | Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen | |
| ES2118593T3 (es) | Analogos de nucleotidos de pteridina como sondas fluorescentes de adn. | |
| ATE221914T1 (de) | Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung | |
| ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
| DE60325016D1 (de) | Oligonukleotide mit alternierenden segmenten und deren verwendungen | |
| ATE196912T1 (de) | Propargylethoxyamino nucleotide | |
| RU98105786A (ru) | Модифицированные праймеры | |
| ES2243007T3 (es) | Sintesis quimica completa y sintesis de genes de genomas. | |
| ATE432284T1 (de) | Einen starren linker enthaltende nukleotide | |
| DK0517796T3 (da) | Oligonukleotid-analoger | |
| DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
| ATE324440T1 (de) | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen | |
| Pitulle et al. | Initiator oligonucleotides for the combination of chemical and enzymatic RNA synthesis | |
| ATE163973T1 (de) | Antisense oligonukleotidhemmung von papillomavirus | |
| DE69815370D1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
| NO972868L (no) | Oligonukleotid-dendrimer konjugater | |
| ATE160354T1 (de) | Oligonukleotide mit anti-cytomegalovirus wirkung | |
| WO2001020017A3 (en) | Metal cluster containing nucleotides and nucleic acids, and intermediates therefor | |
| DE60024464D1 (de) | Hohe dichte markierung von dns mit modifizierte oder chromophore tragende nukleotide und benutzte dns polymerasen | |
| DE69726276D1 (de) | In situ herstellung von nukleosid-phosphoramiditen und ihre verwendung in der oligonukleotidsynthese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |